Business Context and Reporting Period
Company: Wrap Technologies, Inc. (WRAP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025 (Q3 2025)
Business Overview: Wrap Technologies develops public safety products and training services, primarily the BolaWrap remote restraint device, VR training systems, and body-worn camera solutions. The company recently expanded into counter-unmanned aircraft systems (C-UAS) and managed services following the acquisition of W1 Global assets in February 2025.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Net Revenue | $1,491 | $593 | $3,268 | $3,642 |
| Gross Profit | $883 | $235 | $1,965 | $2,055 |
| Gross Margin | 59% | 40% | 61% | 56% |
| Operating Loss | $(2,761) | $(3,626) | $(9,541) | $(10,934) |
| Net Loss | $(2,773) | $1,990 | $(6,391) | $1,722 |
| Cash and Equivalents | $5,965 | $3,610 (Dec 31, 2024) | $5,965 | $4,867 (Sep 30, 2024) |
| Working Capital | $11,675 | N/A | N/A | N/A |
Note: Q3 2024 Net Income was driven by a $5.6M non-cash gain from the change in fair value of warrant liabilities. Q3 2025 Net Loss reflects the absence of this gain and a $0.5M sales return.
Material Changes vs. Prior Period
- Revenue Volatility: Q3 2025 net revenue increased 151% year-over-year to $1.49M, driven by product sales and new managed services. However, this was offset by a $531,000 sales return related to a distributor strategy change. For the nine months ended Sept 30, 2025, net revenue decreased 10% to $3.27M due to lower product orders, partially offset by W1 managed services revenue.
- Profitability: Operating loss improved by 24% in Q3 2025 ($2.76M) compared to Q3 2024 ($3.63M), primarily due to cost containment initiatives reducing operating expenses by 6%.
- Warrant Liability Reclassification: In June 2025, the company amended warrant terms, reclassifying approximately $12.2M of warrant liabilities to equity. This eliminated the significant non-cash gains/losses on warrant valuation that impacted prior periods' net income.
- Liquidity: Cash balances increased from $3.6M (Dec 31, 2024) to $6.0M (Sep 30, 2025), bolstered by $10.2M in financing proceeds from a Private Placement and Series B Preferred Stock issuance.
Guidance, Outlook, and Risks
- Outlook: Management believes it has sufficient capital to fund operations for the next 12 months. The company is focusing on cost containment, expanding international sales, and integrating managed services (policy and training) to support the BolaWrap go-to-market strategy.
- Product Expansion: Launched WrapVision (body-worn camera) and C-UAS initiatives (MERLIN, PAN-DA) in Q3 2025. These new markets are in early stages with no assurance of commercial success.
- Leadership Changes: CFO Jerry Ratigan departed in October 2025; CEO Scot Cohen assumed the roles of Principal Financial and Accounting Officer. A new Board member, John Shulman, was appointed.
- Risks:
- Customer Concentration: One customer accounted for 93% of Q3 2025 revenue. One customer accounted for 76% of accounts receivable.
- Financing Dilution: Series B Preferred Stock and warrants require stockholder approval (scheduled for Dec 12, 2025) to convert/exercise, which may dilute existing shareholders.
- Supply Chain: Ongoing risks regarding component shortages and logistics delays.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 93% revenue concentration from a single customer in Q3 2025 and the impact of the $531k sales return on future distributor relationships.
- Liquidity Runway: Confirm the $6.0M cash balance is sufficient given the $9.5M operating loss for the nine-month period and the upcoming Series B stockholder vote.
- Warrant Terms: Review the implications of the June 2025 warrant amendments and the pending Series B stockholder approval on future dilution.
- Management Continuity: Assess the impact of the CFO departure and the CEO assuming financial officer roles on internal controls and financial reporting.
- New Product Viability: Evaluate the commercial potential and regulatory hurdles for the new C-UAS and WrapVision product lines.